We respond to NICE recommendation of tumour profiling tests to guide adjuvant chemotherapy decisions for certain patients
Baroness Delyth Morgan, chief executive at Breast Cancer Now, said:
09 May 2024
Breast Cancer Now responds to study highlighting increased risk of second cancers among breast cancer survivors
Dr Simon Vincent, director of research, support and influencing at Breast Cancer Now, said:
25 Apr 2024
Breast Cancer Now responds to new evidence that ‘exhausted’ immune cells in healthy women could be target for breast cancer prevention
Dr Simon Vincent, director of research, support and influencing at Breast Cancer Now, said:
28 Mar 2024
Breast Cancer Now responds to new research into how breast cancer cells become dormant and evade treatment
Dr Simon Vincent, director of research, support and influencing at Breast Cancer Now, said:
26 Mar 2024
Breast Cancer Now responds to new research exploring if AI tool can predict side effects risk from surgery or radiotherapy
Dr Simon Vincent, director of research, support and influencing at Breast Cancer Now, said:
21 Mar 2024
Breast Cancer Now responds to new evidence that exercise can help people with secondary breast cancer
Dr Simon Vincent, director of research, support and influencing at Breast Cancer Now, said:
21 Mar 2024
Breast Cancer Now responds to new data showing pembrolizumab improves breast cancer outcomes regardless of age or menopausal status
Dr Simon Vincent, director of research, support and influencing at Breast Cancer Now, said:
19 Mar 2024
Breast Cancer Now responds to research into new breast cancer monitor that can be worn in a bra
Dr Simon Vincent, director of research, support and influencing at Breast Cancer Now, said:
18 Mar 2024
Breast Cancer Now responds to news of Olivia Munn's breast cancer diagnosis
Sally Kum, associate director of nursing, health information and healthcare professional engagement at Breast Cancer Now, said:
13 Mar 2024
Talazoparib (Talzenna) approved for use on the NHS in Scotland
Responding to the decision by the Scottish Medicines Consortium (SMC) to recommend talazoparib (Talzenna) for use on the NHS in Scotland, Baroness Delyth Morgan, chief executive at Breast Cancer Now, said:
11 Mar 2024
Breast Cancer Now respond to Talazoparib (Talzenna) being approved for use on the NHS in Scotland
Responding to the decision by the Scottish Medicines Consortium (SMC) to recommend talazoparib (Talzenna) for use on the NHS in Scotland, Baroness Delyth Morgan, chief executive at Breast Cancer Now, said:
11 Mar 2024
Breast Cancer Now responds to latest Ombudsman report revealing over-stretched doctors could put cancer patients at risk
Baroness Delyth Morgan, chief executive at Breast Cancer Now, warns:
09 Mar 2024